Categories: Wire Stories

ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor at ESMO Asia

– Proven excellent therapeutic effect with 60% objective response rate and 100% complete remission in patients with NK/T cell lymphoma

SEONGNAM, South Korea–(BUSINESS WIRE)–#ENKTLImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 2 NK/T-cell lymphoma clinical trial of IMC-001, a PD-L1 monoclonal antibody, at the Asian Congress of the European Society for Medical Oncology (ESMO Asia 2022) held in Singapore on December 4th, 2022.

The clinical data demonstrated that 6 out of 10 evaluable patients (60%) achieved an objective response, all of whom showed a complete remission (CR). Additionally, the administration has been continued in 4 of these 6 patients for over a year, which also indicates its outstanding safety (in terms of the long-term toxicity) and durable response.

Thanks to these achievements, the results of IMC-001 were selected for Mini Oral Session at ESMO Asia this year.

Professor Won Seog Kim of Samsung Medical Center, a presenter and Principal Investigator of IMC-001, commented, �The complete remission and response rate of 60% of IMC-001 significantly outperform currently available drugs for the treatment, and very rare adverse events of grade 3 or higher also eliminate concerns over the side effects, making it the best-in-class among PD-(L)1 drugs. These results are expected to satisfy the criteria for approval and lead to globalization of an immune checkpoint inhibitor developed by a Korean biotech.”

NK/T cell lymphoma is a rare cancer that occurs mostly in Asian countries such as China and Korea, and often treated with radiation and chemotherapy. NK/T cell lymphoma has a high recurrence rate of 75% within 2 years. Due to the absence of standard-of-care treatment for relapsed/refractory, it has high unmet needs. So far, no single immuno-oncology drug has obtained approval in this indication across the globe.

IMC-001 is a PD-L1 antibody, an immune checkpoint inhibitor that serves as the basis of the current immuno-oncology market. This antibody activates the anticancer functions of T cells by strongly inhibiting the binding between PD-1 expressed on T cells and PD-L1 expressed on the surface of cancer cells. Moreover, it can mediate ADCC (antibody-dependent cellular cytotoxicity) against tumor cells, as it maintains the Fc effector function using human IgG1.

Heung Tae Kim, CEO of ImmuneOncia said, “This achievement sets a new standard for the second-line treatment of NK/T-cell lymphoma, which has high unmet needs. This will be a momentum to secure more partnering opportunities in regions with a high incidence of NK/T-cell lymphoma, like China. ImmuneOncia is also preparing additional clinical trials to expand its indications in solid cancer.”

ImmuneOncia is a biotechnology company specializing in immuno-oncology drug development, jointly established by Yuhan Corporation of Korea and a Nasdaq-listed Sorrento Therapeutics in the US. In addition to IMC-001, ImmuneOncia has a wide range of new products in the pipeline, such as IMC-002, a CD47 antibody, and IMC-201, a bispecific antibody.

Contacts

ImmuneOncia Therapeutics, Inc.

Jiyoung Chu

+82 31-604-8110

PR@immuneoncia.com

Jeongsik Choi

+82 31-604-8133

BD@immuneoncia.com

Alex

Recent Posts

Experience The Ultimate Adrenaline Rush With Thrill Coaster Singapore Vr Pods At Madame Tussauds Singapore

SINGAPORE - Media OutReach Newswire - 9 January 2025 - Madame Tussauds Singapore is thrilled…

4 hours ago

Gold’s Stellar Growth May Have Reached its Finale, Says VT Markets Latest 2025 Q1 Economic Outlook

HONG KONG SAR - Media OutReach Newswire - 9 January 2025 - Award-winning brokerage VT…

5 hours ago

GJEPC And De Beers Group Forge Strategic Collaboration to Promote Natural Diamonds

As India becomes the world’s fastest growing major diamond jewellery market, industry leaders De Beers…

6 hours ago

O-Level Computing Graduates to Receive Credit Exemption at NYP’s School of Information Technology

A first for the polytechnic, this exemption allows learners to free up and reallocate curriculum…

6 hours ago

SUNRATE Expands Beyond Global Payments in 2025 by Introducing New Treasury Solutions

Newly Launched “Trading and Hedging” Solutions to Empower Businesses with FX Trading, Hedging Strategies and…

7 hours ago

As at 8 January, GDA Secures 84.1% of MAHB Shares

Offer extended to 17 January 2025. Offer Price remains firm at RM11.00 Per Share KUALA…

16 hours ago